Skip to main content
OpenTrials
Completed

NCT Number: NCT00347802

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dr. Noecker

Pittsburgh, Pennsylvania, 15213, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • · Male or female > 18 years of age
  • Naive to treatment or washed off any ocular hypotensive agents
  • Untreated IOP >19 mm Hg
  • Diagnosis of open-angle glaucoma or ocular hypertension
  • Ability to provide informed consent and likely to complete study

Exclusion criteria

  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication
  • Uncontrolled systemic disease
  • Active ocular disease other than glaucoma or ocular hypertension
  • Required use of ocular medications other than the study medications during the study
  • History of intraocular surgery within the last 3 months
  • Prior discontinuation of any of the study medications for reasons related to efficacy or safety

Treatment and study plan

Bimatoprost 0.03%, Travoprost 0.004%

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted
Jul 4, 2006
Registry last updated
Jun 1, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.